Regenerative and peptide-based therapies sit in a regulatory and clinical landscape that is still maturing. Responsible care depends on diagnosis, candidacy assessment, screening labs and imaging, informed consent, and follow-up.
A physician-led model integrates these therapies into a broader plan as considered options selected when clinically appropriate, not as standalone products.
Related care
What this means for patients
- Patients receive a coordinated plan rather than a menu of treatments.
- Risks, benefits, and alternatives are discussed transparently.
What this does not mean
- It does not mean every patient who requests a therapy is a candidate.
- It does not mean outcomes are guaranteed.
Sources
- FDA: Regenerative Medicine Information for Patients
FDA guidance underscores the importance of physician oversight, regulatory compliance, and conservative claims in regenerative care.
Educational content only. Treatment decisions require physician evaluation.
Want to understand whether this applies to you?
Request a Private AssessmentHave imaging, labs, or prior treatment records?
Request a Private Assessment